Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist
Abstract Background ASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) and primary biliary cirrhosis (PBC). Objective The objective of this study was to...
Main Authors: | Handan He, Jinzi J. Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-11-01
|
Series: | Drugs in R&D |
Online Access: | https://doi.org/10.1007/s40268-023-00444-4 |
Similar Items
-
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
by: Islam R. Younis, et al.
Published: (2023-03-01) -
Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study
by: Jia Xu, et al.
Published: (2023-12-01) -
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
by: Ludovico Abenavoli, et al.
Published: (2020-06-01) -
Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases
by: Mohammad Almeqdadi, et al.
Published: (2024-01-01) -
AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC
by: Kowdley, K, et al.
Published: (2011)